Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 9:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 318 matching trials from the live ClinicalTrials.gov search.
Conditions
Advanced Solid Tumors or Hematologic Malignancies
Interventions
APG-1387 for Injection
Drug
Lead sponsor
Ascentage Pharma Group Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
3
States / cities
Ann Arbor, Michigan • Grand Rapids, Michigan • San Antonio, Texas
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
Interventions
Educational Intervention, Patient Navigation, Quality-of-Life Assessment, Questionnaire Administration
Other · Behavioral
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
331 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
264
States / cities
Fairbanks, Alaska • Fort Smith, Arkansas • Antioch, California + 211 more
Completed No phase listed Observational

The Good Patient Study

NCT02199548
Conditions
Solid Tumor, Hematological Malignancies, Brain Tumor
Interventions
Interview
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
12 Years to 19 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Memphis, Tennessee
Conditions
Chronic Myeloproliferative Disorders, Fatigue, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
American ginseng, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
326
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 208 more
Conditions
Anxiety, Depression, Hematopoietic and Lymphatic System Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions
Psychotherapy, Psilocybin, Survey Administration
Behavioral · Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Hematopoietic Neoplasm, Malignant Solid Neoplasm, Lymphatic System Neoplasm
Interventions
Fitbit, Apple HealthKit-based devices
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Francisco, California
Conditions
Neoplasms, Lymphoma, Hematologic Neoplasms
Interventions
TAK-981
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
8
States / cities
La Jolla, California • Boston, Massachusetts • Detroit, Michigan + 5 more
Conditions
Solid Tumors, Hematologic Malignancies
Interventions
INCA036873
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
8
States / cities
Duarte, California • La Jolla, California • Ann Arbor, Michigan + 4 more
Recruiting No phase listed Observational

CIBMTR Research Database

NCT01166009
Conditions
Autologous Stem Cell Transplantation, Allogeneic Stem Cell Transplantation, Solid Tumors, Blood Cancers, CAR-T, Gene Therapy, Non-malignant Disease
Interventions
Not listed
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
Not listed
Enrollment
99,999,999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2050
U.S. locations
2
States / cities
Minneapolis, Minnesota • Milwaukee, Wisconsin
Active, not recruiting Phase 1Phase 2 Interventional Results available

Durvalumab and Tremelimumab for Pediatric Malignancies

NCT03837899
Conditions
Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies
Interventions
Durvalumab / Tremelimumab Combination Therapy
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
0 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
5
States / cities
Baltimore, Maryland • Boston, Massachusetts • New Hyde Park, New York + 2 more
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Nausea and Vomiting, Precancerous Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
ondansetron, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
12
States / cities
Scottsdale, Arizona • Urbana, Illinois • Des Moines, Iowa + 9 more
Conditions
Adenovirus Infection, BK Virus Infection, Cytomegaloviral Infection, Hematopoietic and Lymphoid Cell Neoplasm, JC Virus Infection, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Virus-specific Cytotoxic T-lymphocytes
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Hematologic Malignancy, Solid Malignancy
Interventions
Non Interventional
Other
Lead sponsor
CRISPR Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2038
U.S. locations
17
States / cities
Duarte, California • Los Angeles, California • Stanford, California + 14 more
Conditions
Cancer Patients With Advanced Solid Tumors Including Lymphoma or Chronic Hematological Malignancies
Interventions
LBH589
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Lung Carcinoma, Malignant Digestive System Neoplasm, Malignant Solid Neoplasm
Interventions
Computer-Assisted Intervention, Patient Monitoring, Questionnaire Administration
Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
6 Minute Walk Functional Test, Behavioral Intervention, Survey Administration, Timed Get Up and Go Test
Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
6 Years to 29 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
Dallas, Texas • Houston, Texas
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Pneumonia, Pneumonitis, Severe Acute Respiratory Distress Syndrome, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Tocilizumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Rockville, Maryland • Las Vegas, Nevada • Oklahoma City, Oklahoma + 1 more
Conditions
B-ALL, Hematologic Malignancy, Solid Tumor
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 30 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
7
States / cities
Los Angeles, California • Aurora, Colorado • Philadelphia, Pennsylvania + 4 more
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Interview, Survey Administration
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Breast Carcinoma, Esophageal Carcinoma, Genitourinary System Carcinoma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Lung Carcinoma, Malignant Central Nervous System Neoplasm, Malignant Digestive System Neoplasm, Malignant Solid Neoplasm
Interventions
Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Behavioral Intervention, Electronic Health Record Review, Quality-of-Life Assessment, Questionnaire Administration
Behavioral · Other
Lead sponsor
University of Rochester NCORP Research Base
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
153
States / cities
Kingman, Arizona • Fort Smith, Arkansas • Denver, Colorado + 102 more
Conditions
COVID-19 Infection, COVID-19-Associated Acute Respiratory Distress Syndrome, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Best Practice, Mesenchymal Stem Cell
Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma, Ewing Sarcoma
Interventions
Zilovertamab vedotin
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
6 Months to 25 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
17
States / cities
Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 14 more
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
3'-deoxy-3'-[18F]fluorothymidine
Device
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2027
U.S. locations
1
States / cities
Detroit, Michigan